[
    [
        {
            "time": "2023-10-18",
            "original_text": "Jim Cramer: Diversification Is Good for Offense, Not Just Defense",
            "features": {
                "keywords": [
                    "diversification",
                    "offense",
                    "defense"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Jim Cramer: Diversification Is Good for Offense, Not Just Defense",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Lilly",
                    "shares decline",
                    "drug misses goals"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Pfizer, Lilly shares decline as osteoarthritis drug misses goals in study",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study",
            "features": {
                "keywords": [
                    "Pfizer-Lilly",
                    "painkiller",
                    "misses main goals",
                    "late stage study"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "share price rises",
                    "strong pipeline"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]